Login / Signup
Antibody-drug conjugates targeting HER2-mutant or HER2-(non) amplified solid tumors: is HER2 an agnostic target?
Lorenzo Guidi
Carmine Valenza
Dario Trapani
Curigliano Giuseppe
Published in:
Expert opinion on biological therapy (2023)
Keyphrases
</>
cancer therapy
drug delivery
wild type